Q5106Inj retacrit non-esrd use
Published CMS Medicare Part B payment-limit context for Q5106, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$7.968
per 1000 UNITS · Medicare Part B
Up 1.1%from $7.883 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$8.0937$6.9443
2024-Q4: $7.618; 2025-Q1: $7.469; 2025-Q2: $7.07; 2025-Q3: $7.566; 2025-Q4: $7.851; 2026-Q1: $7.567; 2026-Q2: $7.883; 2026-Q3: $7.968
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Epoetin ingredient family (FDA data as of August 20, 2026).
Retacrit
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Epoetin presentations
3 other CMS codesSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J0885 | Epoetin alfa, non-esrd | $6.876 per 1000 UNITS | $7.305 per 1000 UNITS | Down 5.9% | ||
| Q4081 | Epoetin alfa, 100 units esrd | $0.688 per 100 UNITS | $0.73 per 100 UNITS | Down 5.8% | ||
| Q5105 | Inj retacrit esrd on dialysi | $0.797 per 100 UNITS | $0.788 per 100 UNITS | Up 1.1% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.